Free press releases distribution network?

Agency / Source: Biocompatibles UK Ltd / BTG Plc

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



BTG Announces FDA Acceptance of Wellstat Therapeutics’ New Drug Application for Uridine Triacetate - BTG Announces FDA Acceptance of Wellstat Therapeutics’ New Drug Application for Uridine Triacetate as Antidote to Overexposure to Chemotherapy Drug 5-Fluorouracil (5-FU) - Wellstat.com / BTGplc.com
BTG Announces FDA Acceptance of Wellstat Therapeutics’ New Drug Application for Uridine Triacetate

 

PRZOOM - /newswire/ - London, United Kingdom, 2015/09/10 - BTG Announces FDA Acceptance of Wellstat Therapeutics’ New Drug Application for Uridine Triacetate as Antidote to Overexposure to Chemotherapy Drug 5-Fluorouracil (5-FU) - Wellstat.com / BTGplc.com. LSE: BTG

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

BTG plc announced that Wellstat Therapeutics’ new drug application (NDA) for uridine triacetate has been accepted for review by the United States Food and Drug Administration (FDA)

The NDA seeks FDA approval of uridine triacetate as treatment for patients at risk of serious toxicity following an overdose of the chemotherapy agent 5-fluorouracil (5-FU) and patients exhibiting symptoms of serious toxicity within 96 hours of 5-FU administration. Used in combination with other drugs or radiation, 5-FU is a mainstay of chemotherapy across a variety of solid tumors, including those of the colon, stomach, esophagus, breast, pancreas and head and neck.

The FDA has provided an anticipated Prescription Drug User Fee Act (PDUFA) action date in March 2016. Uridine triacetate is being developed by Wellstat Therapeutics. If approved by the FDA, BTG will market, sell and distribute uridine triacetate for this indication in the US. Wellstat Therapeutics retains certain rights to exercise an option to co-promote uridine triacetate. Terms of the co-promote have not been disclosed.

David M. Wohlstadter, Wellstat’s Chief Strategy Officer and Counsel, commented: “Our partnership with BTG, which will commercialize this important therapy, demonstrates our shared commitment to the oncology community and cancer patients. This important regulatory milestone brings us one step closer to providing the first and only antidote for patients at risk of serious toxicity following an overdose of 5-fluorouracil (5-FU) and patients exhibiting symptoms of serious toxicity within 96 hours of 5-FU administration.”

Carolyn Lewis, BTG’s General Manager of Specialty Pharmaceuticals, commented: “Given how common the use of 5-FU is in patients with solid tumors, the negative health and economic impacts of rapid-onset severe toxicity and unintentional overexposure are significant. This filing by Wellstat Therapeutics underscores our shared commitment to bringing an important potential treatment to patients in critical need of care. If granted, FDA approval of uridine triacetate will provide patients and physicians greater access to this novel, potentially life-saving therapy.”

Published literature as well as historical data suggest that overexposure to 5-FU can result in serious toxicity or death.

In 2009, uridine triacetate received orphan drug designation from the FDA as an antidote in the treatment of 5-fluorouracil poisoning and from the European Medicines Agency (EMA) as a treatment for 5-fluorouracil overdose. Under an expanded access protocol, FDA emergency treatment provisions in the US, and similar emergency use provisions in Europe and the rest of the world, uridine triacetate is currently provided to patients at risk of excess 5-FU toxicity due to overdose and patients exhibiting serious toxicities to 5-FU within 96 hours of 5-FU administration. The NDA for uridine triacetate is based in part on efficacy and safety data from US sites in this protocol.

5-FU is on the World Health Organization’s List of Essential Medicines, a compilation of the most important medications needed in a basic health system. Because 5-FU is administered in different doses and schedules as a frequent component of standard chemotherapy regimens for a variety of cancers, patients can experience dramatically different patterns of toxicity. Overexposure to 5-FU can occur as a result of overdose, genetic variations, impaired clearance or other biochemical factors.

Published literature suggests that each year, approximately 250,000 to 300,000 patients in the US receive multiple treatments with 5-FU, of which 0.5 percent die from 5-FU toxicity. An estimated 10-20 percent of those patients develop serious, sometimes life threatening, 5-FU toxicity or experience an overdose. Non-fatal 5-FU toxicities can result in hospitalization, intensive care utilization and delays in or discontinuation of chemotherapy.

About Uridine Triacetate
Uridine triacetate is an investigational drug currently under review by the FDA for use as a treatment for patients at risk of serious toxicity following an overdose of 5-fluorouracil (5-FU) and patients exhibiting symptoms of serious toxicity within 96 hours of 5-FU administration. Uridine triacetate is converted in the body to uridine, a direct biochemical antagonist of 5-fluorouracil toxicity.

About 5-Fluorouracil (5-FU)
Used in combination with other chemotherapy agents and/or radiation, 5-FU has been for decades a mainstay of various treatment regimens for solid tumors, including those of the colon, stomach, esophagus, breast, pancreas, and head and neck. The drug is most commonly administered by infusion pump at or near what is considered the maximum tolerated dose. Expected side effects of 5-FU include myelosuppression (a reduction in white-blood-cell counts and thus increased risk of infection), diarrhea, nausea, vomiting, and mucositis (a painful inflammation and ulceration of the mucous membranes lining the digestive tract). Overexposure to 5-FU can lead to severe myelosuppression, gastrointestinal hemorrhage, septic shock, multiple organ failure, cardiac and neurological complications and death.

About Wellstat Therapeutics
Wellstat Therapeutics Corporation (wellstat.com) is a privately-held biopharmaceutical company located in Gaithersburg, Maryland. Wellstat Therapeutics is committed to discovering, developing and commercializing products that will provide new and improved treatments for patients in the fields of oncology and metabolic, neurometabolic and neurodegenerative diseases. For more information, please visit the website at wellstattherapeutics.com. Wellstat Therapeutics is part of the Wellstat group of companies.

About BTG
BTG (btgplc.com) is a growing international specialist healthcare company bringing to market innovative products in specialist areas of medicine to better serve doctors and their patients. We have a portfolio of Interventional Medicine products to advance the treatment of liver tumors, advanced emphysema, severe blood clots and varicose veins, and Specialty Pharmaceuticals that help patients overexposed to certain medications or toxins. Inspired by patient and physician needs, BTG is investing to expand its portfolio to address some of today’s most complex healthcare challenges.

Contacts:

BTG
Andy Burrows, VP Corporate & Investor Relations
P: +44(0)20 7575 1741 / M: +44(0)79 9053 0605

Stuart Hunt, Investor Relations Manager
P: +44(0)20 7575 1582 / M: +44(0)78 1577 8536

FTI Consulting
Ben Atwell / Simon Conway
P: +44(0)20 3727 1000

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Biocompatibles UK Ltd / BTG Plc

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


BTG Announces FDA Acceptance of Wellstat Therapeutics’ New Drug Application for Uridine Triacetate

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
BTG plc | Uridine Triacetate
Contact: Chris Sampson - BTGplc.com 
+44(0)20 7575 1595 / +44(0)7773 251178 (mobile) chris.sampson[.]btgplc.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Biocompatibles UK Ltd / BTG Plc securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read Latest Press Releases From Biocompatibles UK Ltd / BTG Plc / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

BD Announces Adoption of Windows 10 ‘Internet of Things’ for the Pyxis™ ES System
Greenphire Named to Deloitte 2016 Technology Fast 500™
Genentech Showcases New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting
BD Collaborates with JDRF to Focus on Extended Wear Innovations for Insulin Infusion Delivery
BD Launches First Syringe Designed for Use with Humulin® R U-500 Insulin
MDxHealth Announces Unique CPT Code Awarded for ConfirmMDx from the American Medical Association
BD MAX™ Vaginal Panel Receives FDA Market Authorization to Detect Most Common Causes of Vaginal Infections
Greenphire Receives EU-US Privacy Shield Certification
The 2016 Georges Mathé Prize Recognizes Research on the Immunological Determinants of the Response to Breast Cancer Treatment
MDxHealth Announces Agreement with HIFU CLINIC Prostate Cancer Center for Distribution of SelectMDx in Poland

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



PREMIUM Members


Visit  BizJobs.com

Visit  NAKIVO, Inc.

Visit  JobsWare.com







 
  ©2016 PRZOOM — Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today